A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients

Bone Marrow Transplantation

Volumn 38, Issue 2, 2006, Pages 127-134

  Oren, I ^a   Rowe, J M ^a   Sprecher, H ^a   Tamir, A ^a   Benyamini, N ^a   Akria, L ^a   Gorelik, A ^a   Dally, N ^a   Zuckerman, T ^a   Haddad, N ^a   Fineman, R ^a   Dann, E J ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Acute leukemia; Fluconazole; Fungal infections; Hematopoietic stem cell transplantation; Itraconazole

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITRACONAZOLE; LEUKEMIA; MALE; MIDDLE AGED; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33745755772     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705418     Document Type: Article

References (33)

1. Reents S, Goodwin D, Singh V. Antifungal prophylaxis in immunocompromised hosts. Ann Pharmacother 1993; 27: 53-60.
2. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal. Blood 1995; 86: 2063-2072.
3. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomised, double-blind study. J Infect Dis 1995; 171: 1545-1552.
4. Riley DK, Pavia AT, Beatty PG, Peterson FB, Spruance JL, Stokes R et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509-514.
5. O'Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, Ito J et al. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high risk patients. J Clin Oncol 1994; 12: 827-834.
6. Wolff SN, Fay J, Stevens D, Herzig RH Pohlman B, Bolwell B et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25: 853-859.
7. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomised double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
8. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-168.
9. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661.
10. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
11. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
12. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
13. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis Glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849.
14. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
15. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
16. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell recipients. Clin Infect Dis 2002; 34: 909-917.
17. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66: 257-262.
18. Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Expert Opin Pharmacother 2000; 1: 287-304.
19. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dellAdulto. Clin Infect Dis 1999; 28: 250-255.
20. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA et al. Effect of itraconazole in the prevention of fungal infections among neutropenic patients with hematological malignancies and intensive chemotherapy. A double blind placebo controlled study. Leuk Lymph 1993; 11: 353-358.
21. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300-305.
22. Morgenstern GR, Prentice AG, Prentice HG, Ropner GE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies. U.K. Multicenter Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-911.
23. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 2003; 138: 705-713.
24. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplant. Blood 2004; 103: 1527-1533.
25. Ascioglu S, Rex JH de Pauw B, Bennet JE, Bille J, Crokart F et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infection in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international concensus. Clin Infect Dis 2002; 34: 7-14.
26. Marr K, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
27. Harousseau J, Dekker A, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematologic malignancy and profound neutropenia: A randomized, double-blind, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887-1893.
28. Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 2003; 9: 40-45.
29. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
30. Glasmacher A, Hahn C, Molitor E, Sauerbruch T, Marklen G, Schmidt-Wolf IGH. Definition of an itraconazole target concentration for antifungal prophylaxs [Abstract]. Abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2000, Toronto, Canada. American Society for Microbiology: Washington 2000; 363.
31. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
32. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbial Rev 1999; 12: 50-79.
33. Wiederhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, Spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12: 1313-1333.